Peptide based ligand discovery to prevent protein aggregation in neurodegenerative disease conditions

Neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and Huntington’s disease are cognitively and physically debilitating and progressive diseases due to the gradual and irreversible loss of discrete neuronal populations in the brain. In addition to millions of people worldwide suffering from them, the prevalence of the neurodegenerative diseases dramatically increases with the increasing lifespan of the population. Most of the current therapeutic strategies either target toxic aggregates in neurons or support the healthy cells in diseased region. However, these interventions provide only symptomatic relief and deceleration of disease progression. Besides, aggregation involves a locking phase in which irreversible transition of soluble monomeric and oligomeric molecules into insoluble fibrous structures occurs. During aggregation, fragmentation of mature fibrils leads to the formation of new oligomeric structures possessing seeding activity. The seeds behaving as a nucleation unit trigger other structures to join the accumulated proteins. Synthetic biology is an emerging field that suggests therapeutic solutions for several diseases. Development of synthetic proteins such as artificial transcription factors and improved antibodies, artificial cell transplants with controlled secretion, designed inhibitory RNA molecules and antisense oligonucleotides, gene circuits and logic gates, synthetic viruses as an advanced delivery system and genome editing technologies using programmable nucleases are revolutionary approaches for the diagnosis and treatment of diseases. With the utilization of a variety of advanced tools, synthetic biology is extremely promising to treat neurodegenerative disorders too. In this study, biotechnological approaches and tools such as gene cloning, yeast surface display and phage display library have been used to target neurodegenerative proteins before aggregation takes place. Neurodegenerative proteins were cloned into a plasmid DNA within bacteria and displayed on the surface of Saccharomyces cerevisiae cells. A phage display library has been screened against those neurodegenerative proteins and binding peptides of these proteins have been selected following recursive rounds of binding and washing steps. Peptides that bind to neurodegenerative proteins with high affinity possess the potential to block them and prevent the initiation of aggregation. Beside to the promising results of neuroprotective and neurorestorative interventions, this strategy can provide prevention of aggregation which is the underlying cause of neurodegeneration.